Who Supplies Pyrimethamine to India from UNITED STATES

Importing finished pharmaceutical formulations containing Pyrimethamine into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs be registered and approved before distribution. The registration process involves obtaining a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) and submitting Form 40/41 to CDSCO. The timeline for import drug registration varies but typically ranges from 6 to 12 months, depending on the complexity of the product and completeness of the application. For formulations containing Pyrimethamine under HS Code 30046000, specific documentation such as a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data are required.

Imported pharmaceutical formulations must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian Pharmacopoeia standards. Batch-wise testing is mandatory, and a Certificate of Analysis (CoA) must accompany each shipment. Stability data, particularly for ICH Zone IV conditions, are essential to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is conducted to verify the authenticity and quality of the imported products.

Between 2024 and 2026, CDSCO has implemented stricter regulations for the import of pharmaceutical products, including mandatory import registration and licensing. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and the United States have facilitated smoother trade processes, but compliance with updated regulatory requirements remains essential.

India imports finished Pyrimethamine formulations primarily due to the demand for specific dosage forms and branded products not manufactured domestically. The market size for Pyrimethamine formulations in India is substantial, with a total export market of $46.4 million across 70 exporters to 46 countries. Domestic capacity may not fully meet the demand for certain specialized formulations, leading to reliance on imports.

The Basic Customs Duty (BCD) for HS Code 30046000 is 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% and Integrated Goods and Services Tax (IGST) of 12% are applicable. Anti-dumping duties and exemptions may apply based on specific trade agreements and product classifications. The total landed duty percentage varies depending on the product's CIF value and applicable exemptions.

India sources finished Pyrimethamine formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Other suppliers include China and Germany; however, the United States holds a competitive advantage in terms of product innovation and regulatory compliance. The United States's share in India's Pyrimethamine import market is significant, reflecting its strong position as a supplier.

India imports finished Pyrimethamine formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. These products may not be manufactured domestically, necessitating imports to meet patient needs.

Compared to China and the European Union, the United States offers advantages in terms of product innovation, quality assurance, and regulatory compliance. While products from other origins may be available, the United States's adherence to stringent manufacturing practices and regulatory standards provides a unique advantage.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to supply chain disruptions; therefore, importers should develop contingency plans to mitigate these risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align procurement volumes with supplier MOQs to optimize costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Form 40/41: Submit the appropriate form to CDSCO for import registration.
3. 3Drug Import License: Secure a license from CDSCO for importing pharmaceutical products.
4. 4No Objection Certificate (NOC): Obtain an NOC from DGFT for the specific product.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30046000 to confirm duty rates and classifications.

1. 1Certificate of Analysis (CoA): Verify product quality and compliance.
2. 2Certificate of Pharmaceutical Product (CoPP): Confirm regulatory approval in the country of origin.
3. 3Good Manufacturing Practice (GMP) Certificate: Ensure adherence to manufacturing standards.
4. 4Drug Master File (DMF): Provide detailed information about the drug substance.
5. 5Stability Data: Demonstrate product stability under ICH Zone IV conditions.
6. 6Free Sale Certificate: Indicate that the product is freely sold in the country of origin.
7. 7Manufacturer Authorization: Confirm the